Drug Trial Radar · NCT00088504
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
Last checked: Nov 20, 2026Latest source record: Dec 21, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Jul 2004
Primary completion
Not stated
Study completion Oct 2006
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Jul 28, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously responded to this therapy. Approximately 315 subjects will be enrolled in this research study at approximately 55 clinical sites in the United States. There will be three study groups. Everyone in the study will receive Pegasys® (pegylated interferon) and Copegus® (ribavirin) at the normally prescribed doses. Two of the groups will also receive the study drug merimepodib (MMPD) twice a day, one group at each dose level being tested. The third group will take a placebo instead of MMPD, with the Pegasys® and Copegus®. After the first 24 weeks of treatment, blood tests will be done to see if subjects are responding to treatment. If they are responding, they will continue receiving study treatment in the study for another 24 weeks. If they are not responding, they will stop study treatment. Everyone who is responding will be monitored for 24 weeks after the last dose of medication, to see how long the response lasts. Evaluations will be performed during the study to look at the safety of the Pegasys®/Copegus® and MMPD or placebo combination, and to see how the combination is working by measuring Hepatitis C Virus in the blood. At some of the clinical sites performing the study, some subjects may also participate in additional testing to look at the metabolism of the drugs, or to look at the immune response to Hepatitis C virus infection and treatment.
Conditions
- Hepatitis C
- Hepatitis
Interventions
MerimepodibDrug
PEG-Interferon-alpha 2a (Pegasys®)Drug
Ribavirin (Copegus®)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
67 sites in 1 country. Site status is shown where the registry gives one.
Joseph L. Cochran, M.D.
Birmingham, Alabama
Suresh Karne, M.D., Ph.D.
Huntsville, Alabama
Vijayan Balan, M.D.
Phoenix, Arizona
Michael P. DeMicco, M.D.
Anaheim, California
Prahalad B. Jajodia, M.D.
Fresno, California
F. Fred Poordad, M.D.
Los Angeles, California
Ramsey Cheung, M.D.
Palo Alto, California
Myron J. Tong, M.D., Ph.D.
Pasadena, California
Michael T. Bennett, M.D.
San Diego, California
Lisa M. Nyberg, M.D.
San Diego, California
Natalie Bzowej, M.D.
San Francisco, California
Marcelo Kugelmas, M.D.
Englewood, Colorado
Herbert L. Bonkovsky, M.D.
Farmington, Connecticut
Eugene R. Schiff, M.D.
Miami, Florida
Jawahar L. Taunk, M.D.
Palm Harbor, Florida
Arnold L. Lentnek, M.D.
Marietta, Georgia
Ellen B. Hunter, M.D.
Boise, Idaho
Steven L. Flamm, M.D.
Chicago, Illinois
Helen Te, M.D.
Chicago, Illinois
Gerald J. Mingoletti, M.D.
Oak Forest, Illinois
Donald R. Graham, M.D.
Springfield, Illinois
Alvaro G. Koch, M.D.
Lexington, Kentucky
Shaban Faruqui, M.D.
Baton Rouge, Louisiana
Robert M. Be, M.D.
Baton Rouge, Louisiana
Bal Raj Bhandari, M.D.
Monroe, Louisiana
Luis A. Balart, M.D.
New Orleans, Louisiana
Robert Perrillo, M.D.
New Orleans, Louisiana
Michael Epstein, M.D.
Annapolis, Maryland
Natarajan Ravendhran, M.D.
Baltimore, Maryland
Mark Sulkowski, M.D.
Baltimore, Maryland
Milton J. Koch, M.D.
Silver Spring, Maryland
David N. Schwartz, M.D.
Attleboro, Massachusetts
Nezam Afdhal, M.D.
Boston, Massachusetts
Lawton Shick, M.D.
Worcester, Massachusetts
Stuart C. Gordon, M.D.
Detroit, Michigan
John B. Gross, M.D.
Rochester, Minnesota
Jeffrey Rank, M.D.
Saint Paul, Minnesota
Adrian Di Bisceglie, M.D.
St Louis, Missouri
William C. Sloan
Florham Park, New Jersey
Rajendra Prasad Gupta, M.D.
Trenton, New Jersey
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.